Our data suggest the development of an in vivo SASP, the index of which can be measured by quantifying the concurrently expressed soluble factors including but not limited to SPINK1 and IL-8 in the peripheral flood of post-treatment cancer patients. The gene discussed is CXCL8; the disease is cancer.